Different Recent, New and Old Approaches Could Help us to Win the Game Against SARS-COV-2

Different Recent, New and Old Approaches Could Help us to Win the Game Against SARS-COV-2

Amro A. Amara

Contact

Different Recent, New and Old Approaches Could Help us to Win the Game Against SARS-COV-2

Article Fingerprint

ReserarchID

G39E0

Different Recent, New and Old Approaches Could Help us to Win the Game Against SARS-COV-2 Banner

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

SARS-COV-2 is a virus that has led to the death of a large number of persons, and caused a global endemic problem since December 2019. Vaccines have been prepared, and authorized in an argent way to survive lives. Any possible or known tactic has been used to prevent its spreading, treat infected individual, and to understand how it changes its structure to produce, in advance, a pre-made vaccine that could be used in an adequate time. Understanding their antigenIcity, mutation, adaptation, different types of the produced vaccines, its in cito interaction, and the like, are essential to win the battle. Humanity has been winning the battle against some more virulence viruses like smallpox (human virus), and the Rinderpest (animal virus) using strategies that could only describe nowadays as a “simple method.”. This review is concerned with highlighting important issues concerning SARS-COV-2, and its vaccine(s), structure, epitopes, RNA, surface antigens, personalizing the individual different responses, the need for case-by-case treatments, and the like.

References

62 Cites in Article

Reference Format

C Aarti (2020). Antimycobacterium, anticancer, and antiviral properties of probiotics: An overview.
Abd El-Baky,N (2018). The Minimum Inhibition and Growth Concentrations for Controlling Fungal Infections as well as Ghost Cells Preparation: Aspergillus flavus as a Model.
Abd El-Baky,N (2018). Protein and DNA isolation from Aspergillus niger as well as ghost cells formation.
Enrik Aguila,Marie Lontok,Eliezer Aguila (2020). Letter: role of probiotics in the COVID‐19 pandemic.
A Amara (2015). Kostenlos viral ghosts, bacterial ghosts microbial ghosts and more.
Amro Amara (2015). Saccharomyces cerevisiae Ghosts Using the Sponge-Like Re-Reduced Protocol.
Amro Amara (2016). Vaccines against Pathogens: A Review and Food For Thought.
Amro Amara,Mounir Salem-Bekhit,Fars Alanazi (2013). Sponge‐Like: A New Protocol for Preparing Bacterial Ghosts.
A Amara,M Salem-Bekhit,F Alanazi (2014). Plackett-Burman randomization method for bacterial ghosts preparation form E. coli JM109.
A Amara (2014). Evaluation the surface antigen of the Salmonella typhimurium ATCC 14028 ghosts prepared by "SLRP.
I Azagra-Boronat (2020). Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model.
I Balta (2021). Novel Insights into the Role of Probiotics in Respiratory Infections, Allergies, Cancer, and Neurological Abnormalities.
T Barrett (2005). Monograph Rinderpest and peste des petits ruminants: virus plagues of large and small ruminants.
David Baud,Varvara Dimopoulou Agri,Glenn Gibson,Gregor Reid,Eric Giannoni (2020). Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.
D Bento,H Staats,T Gonçalves,O Borges (2015). Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
D Blanco-Melo (1039). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
James Burke,Laura St Clair,Rushika Perera,Roy Parker (2021). SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block.
D Cavanagh,P Britton (2008). Coronaviruses: General Features. In: Encyclopedia of Virology.
Keli Chen,Feng Xiao,Dingwen Hu,Weiwei Ge,Mingfu Tian,Wenbiao Wang,Pan Pan,Kailang Wu,Jianguo Wu (2020). SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production.
Nanshan Chen,Min Zhou,Xuan Dong,Jieming Qu,Fengyun Gong,Yang Han,Yang Qiu,Jingli Wang,Ying Liu,Yuan Wei,Jia'an Xia,Ting Yu,Xinxin Zhang,Li Zhang (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Tsung-Hsien Chen,Ming-Tse Hsu,Ming-Yang Lee,Chu-Kuang Chou (2022). Gastrointestinal Involvement in SARS-CoV-2 Infection.
Young Chung,Veronique Beiss,Steven Fiering,Nicole Steinmetz (2020). COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.
Gabriella D'ettorre,Giancarlo Ceccarelli,Massimiliano Marazzato,Giuseppe Campagna,Claudia Pinacchio,Francesco Alessandri,Franco Ruberto,Giacomo Rossi,Luigi Celani,Carolina Scagnolari,Cristina Mastropietro,Vito Trinchieri,Gregorio Recchia,Vera Mauro,Guido Antonelli,Francesco Pugliese,Claudio Mastroianni (2020). Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.
M Daeschel (1989). Antimicrobial substances from lactic acid bacteria for use as food preservatives.
M Diamond,T.-D Kanneganti (2022). Innate immunity: the first line of defense against SARS-CoV-2.
J Ebinger (2021). Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
N El-Baky,A Amara (2022). Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article.
N El-Baky,A Amara (2014). Newcastle disease virus (LaSota strain) as a model for virus Ghosts preparation using H2O2 bio-critical concentration.
Clément Fage,Mathilde Hénaut,Julie Carbonneau,Jocelyne Piret,Guy Boivin (2022). Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells.
K Habel (1956). Effect on immunity to challenge and antibody response of variation in dosage schedule of rabies vaccine in mice.
Lulu Han,Meng-Wei Zhuang,Yi Zheng,Jing Zhang,Mei-Ling Nan,Pei-Hui Wang,Chengjiang Gao (2020). SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways.
Anamica Hossain,Shammi Akter,Alfi Rashid,Sabik Khair,A Alam (2022). Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
B Hu (2020). Characteristics of SARS-CoV-2 and COVID-19.
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jiaan Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Hui Li,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guangfa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Min Jiang,Gaiping Zhang,Hongliang Liu,Peiyang Ding,Yunchao Liu,Yuanyuan Tian,Yanwei Wang,Aiping Wang (2021). Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
Bulent Kantarcioglu,Omer Iqbal,Joseph Lewis,Charles Carter,Meharvan Singh,Fabio Lievano,Mark Ligocki,Walter Jeske,Cafer Adiguzel,Grigoris Gerotziafas,Jawed Fareed (2022). An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
R Klocke (2013). Respiration, human.
Yoriyuki Konno,Izumi Kimura,Keiya Uriu,Masaya Fukushi,Takashi Irie,Yoshio Koyanagi,Daniel Sauter,Robert Gifford,So Nakagawa,Kei Sato (2020). SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.
A Lauring,E Hodcroft (2021). Genetic Variants of SARS-CoV-2-What Do They Mean?.
Chang Lee,Yunjung Choi,Seung Seo,Seong-Hun Kim,In Kim,Sang Kim,Soo Lee,Seung Lee (2021). Addition of probiotics to antibiotics improves the clinical course of pneumonia in young people without comorbidities: a randomized controlled trial.
Pureum Lee,Chang-Ung Kim,Sang Seo,Doo-Jin Kim (2021). Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.
Jin-Yan Li,Ce-Heng Liao,Qiong Wang,Yong-Jun Tan,Rui Luo,Ye Qiu,Xing-Yi Ge (2020). The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.
M Lombard (2007). A brief history of vaccines and vaccination.
Aroa Lopez-Santamarina,Alexandre Lamas,Alicia Del Carmen Mondragón,Alejandra Cardelle-Cobas,Patricia Regal,José Rodriguez-Avila,José Miranda,Carlos Franco,Alberto Cepeda (2021). Probiotic Effects against Virus Infections: New Weapons for an Old War.
Zheng Low,Nur Zabidi,Ashley Yip,Ashwini Puniyamurti,Vincent Chow,Sunil Lal (2022). SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.
Alessandra Mortellaro,Paola Ricciardi‐castagnoli (2011). From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease.
Lisa Müller,Marcel Andrée,Wiebke Moskorz,Ingo Drexler,Lara Walotka,Ramona Grothmann,Johannes Ptok,Jonas Hillebrandt,Anastasia Ritchie,Denise Rabl,Philipp Ostermann,Rebekka Robitzsch,Sandra Hauka,Andreas Walker,Christopher Menne,Ralf Grutza,Jörg Timm,Ortwin Adams,Heiner Schaal (2021). Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination.
Mark Mulligan,Kirsten Lyke,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen Neuzil,Vanessa Raabe,Ruth Bailey,Kena Swanson,Ping Li,Kenneth Koury,Warren Kalina,David Cooper,Camila Fontes-Garfias,Pei-Yong Shi,Özlem Türeci,Kristin Tompkins,Edward Walsh,Robert Frenck,Ann Falsey,Philip Dormitzer,William Gruber,Uğur Şahin,Kathrin Jansen (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
P Pastoret,P Jones (2004). Veterinary vaccines for animal and public health.
A Schudel,M Lombard (2007). Recommendations of the OIE International Conference on the control of infectious Animal Diseases by Vaccination, Buenos Aires, Argentina, 13 to 16 April 2004.
Jasmine Plummer,Deisy Contreras,Wenjuan Zhang,Aleksandra Binek,Ruan Zhang,Felipe Dezem,Stephanie Chen,Brian Davis,Jorge Sincuir Martinez,Aleksandr Stotland,Simion Kreimer,Elias Makhoul,Saleh Heneidi,Celeste Eno,Bongha Shin,Anders Berg,Susan Cheng,Stanley Jordan,Eric Vail,Jennifer Van Eyk,Margie Morgan (2022). US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response.
O Sharma (2020). A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Jalen Singh,Pranav Pandit,Andrew Mcarthur,Arinjay Banerjee,Karen Mossman (2021). Evolutionary trajectory of SARS-CoV-2 and emerging variants.
Liyan Sui,Yinghua Zhao,Wenfang Wang,Ping Wu,Zedong Wang,Yang Yu,Zhijun Hou,Guangyun Tan,Quan Liu (2021). SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1.
J Suskovich (2010). Supplemental Information 3: <i>I. vitro</i> antimicrobial activity of potentially probiotic lactic acid bacteria strains against different pathogens..
Philip V’kovski,Annika Kratzel,Silvio Steiner,Hanspeter Stalder,Volker Thiel (2020). Coronavirus biology and replication: implications for SARS-CoV-2.
Edward Walsh,Robert Frenck,Ann Falsey,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen Neuzil,Mark Mulligan,Ruth Bailey,Kena Swanson,Ping Li,Kenneth Koury,Warren Kalina,David Cooper,Camila Fontes-Garfias,Pei-Yong Shi,Özlem Türeci,Kristin Tompkins,Kirsten Lyke,Vanessa Raabe,Philip Dormitzer,Kathrin Jansen,Uğur Şahin,William Gruber (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Who (2021). COVID-19 vaccine tracker and landscape.
Leyun Wu,Liping Zhou,Mengxia Mo,Tingting Liu,Chengkun Wu,Chunye Gong,Kai Lu,Likun Gong,Weiliang Zhu,Zhijian Xu (2022). SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2.
Z Wu,J Mcgoogan (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China.
J Yang (2020). A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
P Zhou (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Amro A. Amara. 2026. \u201cDifferent Recent, New and Old Approaches Could Help us to Win the Game Against SARS-COV-2\u201d. Global Journal of Medical Research - K: Interdisciplinary GJMR-K Volume 22 (GJMR Volume 22 Issue K7): .

More Citation Formats

Select Citation Style:

Download Citation

Download Article

GJMR Volume 22 Issue K7
Pg. 1- 7

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-K Classification: NLMC Code: QW 168.5.C8

Submission ReceivedDecember 8, 2022
Peer Review Double Blind
Handling Editor
Accepted December 16, 2022
Published December 30, 2022

Version of record

v1.2

Issue date

January 13, 2023

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 1483

Total Downloads: 55

2026 Trends

Published Article

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]